Xilio Therapeutics, the Waltham-based cancer biotech that rebranded from Akrevia Therapeutics back in early 2020, has made its Wall Street debut. The company raised $117.5 million in an IPO on Friday, selling nearly 7.4 million shares at $16 apiece.
Read More
